BIOGEN INC. Cost of Revenue
BIOGEN INC. (BIIB) reported Cost of Revenue of $661.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-04-29
- BIOGEN INC. cost of goods and services sold for the quarter ending 2026-03-31 was $661.00M, a 5.04% increase year-over-year.
- BIOGEN INC. cost of goods and services sold for the quarter ending 2025-12-31 was $495.50M, a 15.08% decline year-over-year.
- BIOGEN INC. cost of goods and services sold for the quarter ending 2025-09-30 was $674.40M, a 5.59% increase year-over-year.
- BIOGEN INC. cost of goods and services sold for the quarter ending 2025-06-30 was $605.00M, a 10.81% increase year-over-year.
- BIOGEN INC. cost of goods and services sold for fiscal 2025 was $2.40B, a 4.06% increase from fiscal 2024.
- BIOGEN INC. cost of goods and services sold for fiscal 2024 was $2.31B, a 8.80% decline from fiscal 2023.
- BIOGEN INC. cost of goods and services sold for fiscal 2023 was $2.53B, a 11.20% increase from fiscal 2022.
- BIOGEN INC. cost of goods and services sold for fiscal 2022 was $2.28B, a 7.99% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-03-31 | $661.00M 10-Q · filed 2026-04-29 | $1.16B derived: sum of 2 quarters · filed 2026-04-29 | $1.83B derived: sum of 3 quarters · filed 2026-04-29 | $2.44B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $495.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $1.17B derived: sum of 2 quarters · filed 2026-02-06 | $1.77B derived: sum of 3 quarters · filed 2026-02-06 | $2.40B 10-K · filed 2026-02-06 |
| 2025-09-30 | $674.40M 10-Q · filed 2025-10-30 | $1.28B derived: sum of 2 quarters · filed 2025-10-30 | $1.91B 10-Q · filed 2025-10-30 | $2.49B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $605.00M 10-Q · filed 2025-07-31 | $1.23B 10-Q · filed 2025-07-31 | $1.82B derived: sum of 3 quarters · filed 2026-04-29 | $2.46B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $629.30M 10-Q · filed 2026-04-29 | $1.21B derived: sum of 2 quarters · filed 2026-04-29 | $1.85B derived: sum of 3 quarters · filed 2026-04-29 | $2.40B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $583.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $1.22B derived: sum of 2 quarters · filed 2026-02-06 | $1.77B derived: sum of 3 quarters · filed 2026-02-06 | $2.31B 10-K · filed 2026-02-06 |
| 2024-09-30 | $638.70M 10-Q · filed 2025-10-30 | $1.18B derived: sum of 2 quarters · filed 2025-10-30 | $1.73B 10-Q · filed 2025-10-30 | $2.35B derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-06-30 | $546.00M 10-Q · filed 2025-07-31 | $1.09B 10-Q · filed 2025-07-31 | $1.71B derived: sum of 3 quarters · filed 2026-02-06 | $2.37B derived: sum of 4 quarters · filed 2026-02-06 |
| 2024-03-31 | $542.20M 10-Q · filed 2025-05-01 | $1.16B derived: sum of 2 quarters · filed 2026-02-06 | $1.82B derived: sum of 3 quarters · filed 2026-02-06 | $2.41B derived: sum of 4 quarters · filed 2026-02-06 |
| 2023-12-31 | $618.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $1.28B derived: sum of 2 quarters · filed 2026-02-06 | $1.87B derived: sum of 3 quarters · filed 2026-02-06 | $2.53B 10-K · filed 2026-02-06 |
| 2023-09-30 | $659.60M 10-Q · filed 2024-10-30 | $1.25B derived: sum of 2 quarters · filed 2024-10-30 | $1.92B 10-Q · filed 2024-10-30 | $2.49B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $592.70M 10-Q · filed 2024-08-01 | $1.26B 10-Q · filed 2024-08-01 | $1.83B derived: sum of 3 quarters · filed 2025-02-12 | $2.30B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $662.80M 10-Q · filed 2024-04-24 | $1.23B derived: sum of 2 quarters · filed 2025-02-12 | $1.70B derived: sum of 3 quarters · filed 2025-02-12 | $2.19B derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $570.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.04B derived: sum of 2 quarters · filed 2025-02-12 | $1.52B derived: sum of 3 quarters · filed 2025-02-12 | $2.28B 10-K · filed 2025-02-12 |
| 2022-09-30 | $469.50M 10-Q · filed 2023-11-08 | $953.50M derived: sum of 2 quarters · filed 2023-11-08 | $1.71B 10-Q · filed 2023-11-08 | $2.37B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $484.00M 10-Q · filed 2023-07-25 | $1.24B 10-Q · filed 2023-07-25 | $1.90B derived: sum of 3 quarters · filed 2024-02-14 | $2.41B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $753.90M 10-Q · filed 2023-04-25 | $1.41B derived: sum of 2 quarters · filed 2024-02-14 | $1.93B derived: sum of 3 quarters · filed 2024-02-14 | $2.39B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $660.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $1.17B derived: sum of 2 quarters · filed 2024-02-14 | $1.63B derived: sum of 3 quarters · filed 2024-02-14 | $2.11B 10-K · filed 2024-02-14 |
| 2021-09-30 | $511.80M 10-Q · filed 2022-10-25 | $971.50M derived: sum of 2 quarters · filed 2022-10-25 | $1.45B 10-Q · filed 2022-10-25 | $1.94B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $459.70M 10-Q · filed 2022-07-20 | $937.80M 10-Q · filed 2022-07-20 | $1.43B derived: sum of 3 quarters · filed 2023-02-15 | $1.88B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $478.10M 10-Q · filed 2022-05-03 | $968.70M derived: sum of 2 quarters · filed 2023-02-15 | $1.42B derived: sum of 3 quarters · filed 2023-02-15 | $1.83B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $490.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $939.70M derived: sum of 2 quarters · filed 2023-02-15 | $1.35B derived: sum of 3 quarters · filed 2023-02-15 | $1.81B 10-K · filed 2023-02-15 |
| 2020-09-30 | $449.10M 10-Q · filed 2021-10-20 | $860.20M derived: sum of 2 quarters · filed 2021-10-20 | $1.31B 10-Q · filed 2021-10-20 | $1.76B derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $411.10M 10-Q · filed 2021-07-22 | $865.50M 10-Q · filed 2021-07-22 | $1.31B derived: sum of 3 quarters · filed 2022-02-03 | $1.74B derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $454.30M 10-Q · filed 2021-04-22 | $901.40M derived: sum of 2 quarters · filed 2022-02-03 | $1.33B derived: sum of 3 quarters · filed 2022-02-03 | $1.81B derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | $447.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $877.10M derived: sum of 2 quarters · filed 2022-02-03 | $1.35B derived: sum of 3 quarters · filed 2022-02-03 | $1.96B 10-K · filed 2022-02-03 |
| 2019-09-30 | $430.00M 10-Q · filed 2020-10-21 | $906.30M derived: sum of 2 quarters · filed 2020-10-21 | $1.51B 10-Q · filed 2020-10-21 | $2.00B derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | $476.30M 10-Q · filed 2020-07-22 | $1.08B 10-Q · filed 2020-07-22 | $1.57B derived: sum of 3 quarters · filed 2021-02-03 | $2.03B derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $602.00M 10-Q · filed 2020-04-23 | $1.09B derived: sum of 2 quarters · filed 2021-02-03 | $1.55B derived: sum of 3 quarters · filed 2021-02-03 | $1.97B derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $488.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $949.30M derived: sum of 2 quarters · filed 2021-02-03 | $1.37B derived: sum of 3 quarters · filed 2021-02-03 | $1.82B 10-K · filed 2021-02-03 |
| 2018-09-30 | $460.80M 10-Q · filed 2019-10-22 | $881.80M derived: sum of 2 quarters · filed 2019-10-22 | $1.33B 10-Q · filed 2019-10-22 | $1.84B derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-06-30 | $421.00M 10-Q · filed 2019-07-24 | $867.00M 10-Q · filed 2019-07-24 | $1.38B derived: sum of 3 quarters · filed 2020-02-06 | $1.75B derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-03-31 | $446.00M 10-Q · filed 2019-04-24 | $955.20M derived: sum of 2 quarters · filed 2020-02-06 | $1.33B derived: sum of 3 quarters · filed 2020-02-06 | $1.69B derived: sum of 4 quarters · filed 2020-02-06 |
| 2017-12-31 | $509.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $879.20M derived: sum of 2 quarters · filed 2020-02-06 | $1.25B derived: sum of 3 quarters · filed 2020-02-06 | $1.63B 10-K · filed 2020-02-06 |
| 2017-09-30 | $370.00M 10-Q · filed 2018-10-23 | $736.20M derived: sum of 2 quarters · filed 2018-10-23 | $1.12B 10-Q · filed 2018-10-23 | |
| 2017-06-30 | $366.20M 10-Q · filed 2018-07-24 | $750.80M 10-Q · filed 2018-07-24 | ||
| 2016-12-31 | $1.48B 10-K · filed 2019-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |